左甲状腺素联合左三碘甲状腺原氨酸与单药治疗甲减的获益与风险:系统评价与Meta分析
该系统评价与Meta分析比较左甲状腺素(LT4)/左三碘甲状腺原氨酸(LT3)联合治疗与LT4单药治疗成人甲减的获益与风险。检索MEDLINE等数据库至2020年9月,纳入18项研究。低至中等确定性证据显示两组在临床状态、生活质量、心理困扰、抑郁症状和疲劳方面无差异;患者更倾向于选择联合治疗(43% vs 23% vs 无偏好30%),不良事件比例相似但仅作叙述性分析。
要点
- 低至中等确定性证据显示联合治疗与单药治疗在临床结局上无差异。
- 患者偏好联合治疗的比例(43%)高于单药治疗(23%)或无偏好(30%)。
- 不良事件和不良反应比例两组相似,但仅为叙述性评估。
核心结论
- 低至中等确定性证据表明,LT4/LT3联合治疗与LT4单药治疗成人甲减在临床结局上无差异。
- 患者偏好联合治疗的比例更高,不良事件和不良反应比例相似但仅作叙述性分析。
研究设计与样本
- 系统检索MEDLINE、Scopus、EMBASE、Web of Science和Cochrane对照试验中心注册库,从建库至2020年9月。
- 纳入比较LT4/LT3联合治疗与LT4单药治疗成人甲减的随机临床试验和准实验研究,共18项研究符合纳入标准。
- 由配对评价者独立提取数据,对临床结局和患者偏好进行标准化均数差的Meta分析,不良事件比例作叙述性评估。
主要发现
- 低至中等确定性证据未显示两种治疗在临床状态、生活质量、心理困扰、抑郁症状和疲劳方面存在治疗效应差异(均用标准化问卷测量)。
- 患者偏好Meta分析显示选择联合治疗的比例为43%,选择单药治疗为23%,无偏好为30%。
- 不良事件或不良反应比例在治疗组间相似,但无法进行Meta分析。
临床怎么用
- 临床医生可与甲减患者共享决策,讨论联合治疗与单药治疗在临床结局上无差异但患者偏好联合治疗的信息。
- 对于考虑联合治疗的患者,应告知不良事件和不良反应比例与单药治疗相似,但证据仅为叙述性。
局限性
- 证据确定性为低至中等。
- 不良事件和不良反应仅作叙述性评估,未进行Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Combined therapy with levothyroxine (LT4)/L-triiodothyronine (LT3) has garnered attention among clinicians and patients as a potential treatment alternative to LT4 monotherapy. The objective of this study was to compare the benefits and harms of LT4/LT3 combined therapy and LT4 monotherapy for patients with hypothyroidism. Methods: A systematic search in MEDLINE, Scopus, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials was performed by a librarian from inception date until September 2020. Randomized clinical trials and quasiexperimental studies comparing combined therapy (LT4/LT3) versus monotherapy (LT4) for adult patients with hypothyroidism were considered for inclusion. Independent data extraction was performed by paired reviewers. A meta-analysis comparing standardized mean differences of the effect of each therapy was performed on clinical outcomes and patient preferences. Proportions of adverse events and reactions were assessed narratively. Results: A total of 1398 references were retrieved, from which 18 fulfilled the inclusion criteria. Results supported by evidence at low-to-moderate certainty evidence did not display a difference in treatment effect between therapies on clinical status, quality of life, psychological distress, depressive symptoms, and fatigue; all measured with standardized questionnaires. Furthermore, meta-analysis of patient preferences revealed higher proportions of choice for combined therapy (43%) when compared with monotherapy (23%) or having no preference (30%). When evaluating treatment adverse events or adverse reactions, similar proportions were observed between treatment groups; meta-analysis was not possible. Conclusions: The available evidence at low-to-moderate certainty demonstrates that there is no difference in clinical outcomes between LT4/LT3 combined therapy and LT4 monotherapy for treating hypothyroidism in adults, except for a higher proportion of patient preferring combined therapy. Adverse events and reactions appear to be similar across both groups, however, this observation is only narrative. These results could inform shared decision-making conversations between patients with hypothyroidism and their clinicians. PROSPERO Registration ID: CRD42020202658.
引用
- Millan-Alanis JM, González-González JG, Flores-Rodríguez A, et al. Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis. Thyroid. 2021. PMID: 34340589. doi:10.1089/thy.2021.0270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。